← Oncology Approval Tracker

FDA DECISION ·

Darzalex Faspro + VRd

daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide and dexamethasone · Janssen Research & Development

FDA approvalNew or expanded indicationMultiple myeloma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Induction and consolidation with the subcutaneous daratumumab combination for patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant.

LAMPGEN ANALYSIS

Why it matters

The label added an anti-CD38 quadruplet to treatment phases around transplant.

What research teams should watch

Coordinate blood-bank testing and stem-cell collection early and keep induction, transplant and consolidation dates distinct.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Newly diagnosed, transplant-eligible myeloma

PRIMARY RECORDS

Sources